KinasePro

Kinase Chemistry – Just a year and a half behind the times.

Motesanib: A little too good.

Posted by kinasepro on November 20, 2008

Looks like this one might be coming off the ph3 list

O=C(NC1=CC=C(C(C)(C)CN2)C2=C1)C3=CC=CN=C3N([H])CC4=CC=NC=C4

Motesanib‘s got “higher early mortality rates

Advertisements

15 Responses to “Motesanib: A little too good.”

  1. Ed said

    AZ’s Zactima Phase III data were released yesterday also, and seemed less than impressive to me (no numbers provided – but maybe they are embargoed for an upcoming conference?), with no statistical significance for the OS improvement endpoint.

  2. Orgmed said

    AMG-706 is diphosphate. Is this the multi-targeted?. 125 mg per day….?
    Lower doses may work.

  3. goldilocks said

    Any idea what’s going on with AMG-273?

  4. milkshake said

    KinasePro: have you noticed Kinasecentral from CrimsonCanary, http://www.kinasecentral.com/ ?

  5. kinasepro said

    read own blog much?

    meh. I’ve been performing a silent experiment wondering when she’d get around to linking to KP.

  6. weirdo said

    I think you’re going to wait a long time. Linking to free sites when one is trying to sell something is seldom a good idea.

    And KinaseCentral needs some quality control. A headline describing a Pfizer disclosure on CP-690,550 links to the JMedChem paper on CP-690,550 from an NIH lab. Reading the by-line helps, ya know?

  7. kinasepro said

    Umm, but uh – dude it had the work kinase in it?

  8. milkshake said

    I know, just headlines devoid of (free) analysis – but still, there are so many BMCL papers and industry announcements that if someone pre-reads them for me, it saves me from wadding through all that low-grade stuff. I found recently some BCML ASAP articles through KinaseCentral that could actually help us with a project.

  9. ROCK inhibitor from Bayer Schering. Current cover of ChemMedChem

  10. DisgruntledViewer said

    What do any of these comments have to do with the article? Is this an “educated” website, or is everyone here to advertise and complain about unrelated topics? This article was supposed to be about Motesanib and no one even metions it once…

  11. kinasepro said

    Educated? nah… We’re more like the peanut gallery.

  12. milkshake said

    …and some people have a peanut allergy. Anyway, I hope that the corporate lawyers and other due-diligence imbeciles won’t harass you for KinasePro, and that you will have energy and time to continue writing about kinase compounds in the next year. Happy holiday!

  13. Woodward said

    You people really spend your time talking about and promoting small molecule kinase inhibitors? Highly selective, multi-target, blah, blah, blah. These compounds have killed more rats than Terminex. The highest concentrations of an orally administered kinase inhibitors are in the GI (mM) and the liver (uM)…they saturate the cytosol in the GI and other organs long before they ever make it to target tissue. Intestinal paralysis, elevated liver enzymes, organs swelling and shrinking. The whole kinase inhibitor thrust has been a quagmire. Our collections are now full of kinase inhibitors that have been a complete waste of chemistry resources.

  14. nerdase said

    gleevec might evade GI tox partially owing to the fact as a prodrug. its active metabolite is 3~5x more potent. it is curious that few people in the field paid much attent to the later. It could a way to go for future kianse inhibitors. btw sorafenib has 5x and 3x higher accumulation in liver and kidney comparing to blood. no wonder it got approved in hcc and rcc.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

 
%d bloggers like this: